Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.6.1.2 (alanine aminotransferase)
 26,722 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A study of the hepatic effects of Gravistat on 240 women is presented. 200 of the women had previously used either Ovosiston or Non-Ovlon continually for an average of 5.6 years, while the remaining 40 had used no hormonal contraceptives for the preceeding 3 months. After 3 weeks of Gravistat use, GOT, GPT, LP-X, and cholesterol levels were taken. 1/4 of the women in both groups showed pathological serum transaminase levels, and the cholesterol levels in both groups were within normal levels. 10 of the women who had previously used hormonal contraceptives, and none from the other group, showed a positive LP-X. A hepatological examination, including a liver biopsy, was performed on 30 of the women with pathological transaminase levels and/or positive LP-X. Pathological conditions (toxic hepatosis, infectious hepatitis, fatty liver) were found in 11 of those cases, while the rest showed metabolic activation. Intrahepatic cholestasis does not seem to be the major factor in the liver damage.
 ...
PMID:[Incidence of toxic liver lesions due to Gravistat]. 64 55

Toxic hepatosis was discovered in 5 women, 24-41 years of age, who had used oral contraceptives for from 3-7 years. In all cases, elevated GPT levels were observed. None of the patients was suffering from viral hepatitis. Toxic hepatosis and viral hepatitis can have similar clinical pictures, and viral hepatitis cannot be automatically ruled out in cases of patients who use oral contraceptives and thus are expected to have toxic hepatosis.
 ...
PMID:[Toxic liver diseases after hormonal contraception]. 73 91